Document is current
Any future updates will be listed below
-
Authors
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02254486 at ClinicalTrials.govnct02273167 at ClinicalTrials.govDocuments that mention this clinical trial
Transient alterations in plasma sodium concentrations with NER1006 bowel preparation: an analysis of three phase III, randomized clinical trials
https://doi.org/10.1186/s12876-022-02484-7
Bowel preparation with 1L polyethylene glycol and ascorbate NER1006 doubles the chance to detect three or more adenomas in overweight or obese males
https://doi.org/10.1055/a-1499-6681
nct02273141 at ClinicalTrials.govDocuments that mention this clinical trial
Colon cleansing efficacy and safety with 1 L NER1006 versus 2 L polyethylene glycol + ascorbate: a randomized phase 3 trial
https://doi.org/10.1055/a-0638-8125
Transient alterations in plasma sodium concentrations with NER1006 bowel preparation: an analysis of three phase III, randomized clinical trials
https://doi.org/10.1186/s12876-022-02484-7
Bowel preparation with 1L polyethylene glycol and ascorbate NER1006 doubles the chance to detect three or more adenomas in overweight or obese males
https://doi.org/10.1055/a-1499-6681
Documents that mention this clinical trial
Colon cleansing efficacy and safety with 1 L NER1006 versus sodium picosulfate with magnesium citrate: a randomized phase 3 trial
https://doi.org/10.1055/a-0639-5070
Transient alterations in plasma sodium concentrations with NER1006 bowel preparation: an analysis of three phase III, randomized clinical trials
https://doi.org/10.1186/s12876-022-02484-7
-
Funding
Funding for this research was provided by:
Norgine Ltd (Original trials)
Norgine Ltd. and Salix Pharmaceuticals (Post hoc analyses)
Salix Pharmaceuticals (Technical editorial, medical writing assistance)
- License Information
-
More Information
Article History
Received: 15 November 2021
Accepted: 14 August 2022
First Online: 5 September 2022
Declarations
:
: All three previously published trials received Institutional Review Board (IRB) approval from a centralized IRB (Quorum Review IRB, Seattle, WA [NOCT]) or the IRB of each study center (MORA, DAYB) and were conducted in accordance with International Conference on Harmonisation Guidelines for Good Clinical Practice and ethical principles of the Declaration of Helsinki. All patients provided written informed consent for participation.
: Not applicable.
: BDC reports serving as a consultant and speaker for Salix Pharmaceuticals. CA is an employee of Salix Pharmaceuticals. DMP reports serving as a consultant and educator for Olympus Medical; and serving as a consultant for Salix Pharmaceuticals.
